Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 60


The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.

Rafiei A, Mian AA, Döring C, Metodieva A, Oancea C, Thalheimer FB, Hansmann ML, Ottmann OG, Ruthardt M.

PLoS Genet. 2015 Apr 28;11(4):e1005144. doi: 10.1371/journal.pgen.1005144. eCollection 2015 Apr.


STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML.

Oancea C, Rüster B, Brill B, Roos J, Heinssmann M, Bug G, Mian AA, Guillen NA, Kornblau SM, Henschler R, Ruthardt M.

Genes Cancer. 2014 Nov;5(11-12):378-92.


PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

Mian AA, Rafiei A, Haberbosch I, Zeifman A, Titov I, Stroylov V, Metodieva A, Stroganov O, Novikov F, Brill B, Chilov G, Hoelzer D, Ottmann OG, Ruthardt M.

Leukemia. 2015 May;29(5):1104-14. doi: 10.1038/leu.2014.326. Epub 2014 Nov 14.


5-Lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia.

Roos J, Oancea C, Heinssmann M, Khan D, Held H, Kahnt AS, Capelo R, la Buscató E, Proschak E, Puccetti E, Steinhilber D, Fleming I, Maier TJ, Ruthardt M.

Cancer Res. 2014 Sep 15;74(18):5244-55. doi: 10.1158/0008-5472.CAN-13-3012. Epub 2014 Jul 31.


Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.

Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M, Falkenburg JH, Ruthardt M, Ottmann OG.

PLoS One. 2013 Nov 14;8(11):e80070. doi: 10.1371/journal.pone.0080070. eCollection 2013.


Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines.

Najajreh Y, Khamaisie H, Ruimi N, Khatib S, Katzhendler J, Ruthardt M, Mahajna J.

Mol Biol Rep. 2013 Mar;40(3):2205-13. doi: 10.1007/s11033-012-2282-8. Epub 2012 Dec 5.


Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.

Khateb M, Ruimi N, Khamisie H, Najajreh Y, Mian A, Metodieva A, Ruthardt M, Mahajna J.

BMC Cancer. 2012 Nov 27;12:563. doi: 10.1186/1471-2407-12-563.


Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.

Mian AA, Metodieva A, Badura S, Khateb M, Ruimi N, Najajreh Y, Ottmann OG, Mahajna J, Ruthardt M.

BMC Cancer. 2012 Sep 17;12:411. doi: 10.1186/1471-2407-12-411.


Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells.

Romanski A, Schwarz K, Keller M, Wietbrauk S, Vogel A, Roos J, Oancea C, Brill B, Krämer OH, Serve H, Ruthardt M, Bug G.

Cell Cycle. 2012 Sep 1;11(17):3219-26. doi: 10.4161/cc.21565. Epub 2012 Aug 16.


p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.

Mian AA, Metodieva A, Najajreh Y, Ottmann OG, Mahajna J, Ruthardt M.

Haematologica. 2012 Feb;97(2):251-7. doi: 10.3324/haematol.2011.047191. Epub 2011 Nov 4.


The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.

Rettinger E, Kuçi S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, Willasch A, Koehl U, Bug G, Ruthardt M, Klingebiel T, Fulda S, Bader P.

Cytotherapy. 2012 Jan;14(1):91-103. doi: 10.3109/14653249.2011.613931. Epub 2011 Oct 6.


Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/RARα.

Steinert G, Oancea C, Roos J, Hagemeyer H, Maier T, Ruthardt M, Puccetti E.

PLoS One. 2011;6(7):e22540. doi: 10.1371/journal.pone.0022540. Epub 2011 Jul 19.


Oleic acid is the active component in the mushroom Daedalea gibbosa inhibiting Bcr-Abl kinase autophosphorylation activity.

Khamaisie H, Sussan S, Tal M, Najajreh Y, Ruthardt M, Mahajna J.

Anticancer Res. 2011 Jan;31(1):177-83.


The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation.

Oancea C, Rüster B, Henschler R, Puccetti E, Ruthardt M.

Leukemia. 2010 Nov;24(11):1910-9. doi: 10.1038/leu.2010.180. Epub 2010 Sep 9.


The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.

Bursen A, Schwabe K, Rüster B, Henschler R, Ruthardt M, Dingermann T, Marschalek R.

Blood. 2010 Apr 29;115(17):3570-9. doi: 10.1182/blood-2009-06-229542. Epub 2010 Mar 1.


5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis.

Steinhilber D, Fischer AS, Metzner J, Steinbrink SD, Roos J, Ruthardt M, Maier TJ.

Front Pharmacol. 2010 Dec 24;1:143. doi: 10.3389/fphar.2010.00143. eCollection 2010.


Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment.

Zheng X, Oancea C, Henschler R, Moore MA, Ruthardt M.

PLoS One. 2009 Oct 30;4(10):e7661. doi: 10.1371/journal.pone.0007661.


Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL.

Mian AA, Oancea C, Zhao Z, Ottmann OG, Ruthardt M.

Leukemia. 2009 Dec;23(12):2242-7. doi: 10.1038/leu.2009.194. Epub 2009 Oct 1.


Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome.

Boehrer S, Adès L, Tajeddine N, Hofmann WK, Kriener S, Bug G, Ottmann OG, Ruthardt M, Galluzzi L, Fouassier C, Tailler M, Olaussen KA, Gardin C, Eclache V, de Botton S, Thepot S, Fenaux P, Kroemer G.

Oncogene. 2009 Jun 4;28(22):2205-18. doi: 10.1038/onc.2009.69. Epub 2009 Apr 27.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk